$1.40
0.00%
Nasdaq, Oct 02, 04:00 pm EDT. Closed.
ISIN
US45674E1091
Symbol
INAB

IN8bio Inc Stock price

$1.40
+0.30 27.27% 1M
-0.04 2.78% 6M
-0.94 40.17% YTD
-0.89 38.86% 1Y
-29.80 95.51% 3Y
-211.00 99.34% 5Y
-298.60 99.53% 10Y
-298.60 99.53% 20Y
Nasdaq, Closing price Fri, Oct 02 2026
+0.00 0.00%
ISIN
US45674E1091
Symbol
INAB
Industry

Is IN8bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
$13.8m
Enterprise Value
$-4.0m
Net debt
positive
Cash
$18.0m
Shares outstanding
9.9m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
0.3 | 0.2
P/B
0.8
Financial Health
Equity Ratio
85.4%
Return on Equity
-70.5%
ROCE
-98.5%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$2.2m | -
SBC as % of FCF
-
SBC Growth 1Y
-50.7%
Share Count Growth 1Y
141.4%
Shareholder Yield
-141.4%
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
$-17.8m
EBIT
$-19.2m
Net Income
$-18.7m
Free Cash Flow | ex SBC
$-14.6m | $-16.8m
Growth
Revenue | estimate
- | -
EBITDA
19.8%
EBIT
20.6%
Net Income
21.9%
Free Cash Flow
15.2%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-1.0
FCF per Share
$-1.5
Short interest
0.7%
Employees
17
Rev per Employee
$0.0

IN8bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a IN8bio Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a IN8bio Inc forecast:

Buy
90%
Hold
10%

Financial data from IN8bio Inc

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.34 9.34
19% 19%
-
- Research and Development Expense 9.86 9.86
20% 20%
-
-18 -18
20% 20%
-
- Depreciation and Amortization 1.40 1.40
30% 30%
-
EBIT (Operating Income) EBIT -19 -19
21% 21%
-
Net Profit -19 -19
22% 22%
-

In millions USD.

Don't miss a Thing! We will send you all news about IN8bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

IN8bio Inc Stock News

Neutral
GlobeNewsWire
●
25 days ago
Renowned γδ T cell and T cell engager (TCE) expert brings two decades of drug discovery and development experience to IN8bio Appointment strengthens IN8bio's leadership and domain expertise as they advance their novel γδ T cell engager platform NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (...
Neutral
GlobeNewsWire
●
3 months ago
First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma Repeat-dose patients achieved median progression-free survival (mPFS) of 16.1 months, more than double the ~6.9-month standard of care benchmark, with no dose-limiting toxicities (DLTs) NEW YORK, July 09, 2026 (GLOBE NEWSWIRE...
Neutral
GlobeNewsWire
●
4 months ago
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, today announced the publication of a review article titled: “Harnessing γδ T cells through engineering and combination therapies” in the journal Nature Communicat...
More IN8bio Inc News

Company Profile

IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.

Head office United States
CEO Mr. Ho
Employees 17
Founded 2016
Website www.in8bio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today